Trial Profile

Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms C-TASK FORCE

Most Recent Events

28 Jul 2017 Primary endpoint (4 month progression free survival by central assessment) has been met, as per results published in the Lancet Oncology.
28 Jul 2017 Results published in the Lancet Oncology
07 Aug 2015 Status changed from active, no longer recruiting to completed as per University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com